scholarly journals POTENTIAL OF THE MODERN ACE INHIBITOR ZOFENOPRIL IN CLINICAL PRACTICE: CARDIOPROTECTIVE, ANTI-ISCHEMIC, AND ANTIATHEROGENIC EFFECTS

2013 ◽  
Vol 12 (1) ◽  
pp. 102-110
Author(s):  
M. G. Bubnova
Keyword(s):  
Myocardial Infarction ◽  
Cardiovascular Disease ◽  
Acute Myocardial Infarction ◽  
Clinical Practice ◽  
Angiotensin Converting Enzyme ◽  
Ace Inhibitor ◽  
Clinical Effectiveness ◽  
Inhibitor Therapy ◽  
Converting Enzyme

The review discusses various aspects of angiotensin-converting enzyme (ACE) inhibitor therapy in patients with cardiovascular disease (CVD), including acute myocardial infarction (AMI). The focus is on the modern ACE inhibitor zofenopril, its specific pharmacological characteristics, and additional cardioprotective, anti-ischemic, and antiatherogenic effects. The existing evidence of clinical effectiveness of zofenopril and its potential for a wider use in clinical practice are also addressed. 

scholarly journals Capacities of the current angiotensin-converting enzyme inhibitor zofenopril in clinical practice: cardioprotective, anti-ischemic, and antiatherogenic effects

2013 ◽  
Vol 4 (1) ◽  
pp. 62-71
Author(s):  
M. G Bubnova
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Clinical Practice ◽  
Cardiovascular Diseases ◽  
Angiotensin Converting Enzyme ◽  
Ace Inhibitor ◽  
Enzyme Inhibitor ◽  
Pharmacological Properties ◽  
Converting Enzyme ◽  
The Given

The given review discusses the use of angiotensin-converting enzyme (ACE) inhibitors in patients with cardiovascular diseases, including those with prior acute myocardial infarction. The paper places particular emphasis on the currently available ACE inhibitor zofenopril. It discusses its special pharmacological properties and considers its additional effects associated with cardioprotective, anti-ischemic, antiatherogenic effects. The review provides a rationale for the clinical efficacy of zofenopril and a possibility for its wider clinical application.

Angiotensin-Converting Enzyme Gene Polymorphism and Erythropoietin Requirement

2003 ◽  
Vol 23 (2) ◽  
pp. 111-115 ◽  
Author(s):  
Mira Varagunam ◽  
Daniel J. McCloskey ◽  
Paul J. Sinnott ◽  
Martin J. Raftery ◽  
Muhammed M. Yaqoob
Keyword(s):  
Renal Failure ◽  
Parathyroid Hormone ◽  
Angiotensin Converting Enzyme ◽  
Ace Inhibitor ◽  
Inhibitor Therapy ◽  
Converting Enzyme ◽  
C Reactive Protein ◽  
Dose Requirement ◽  
Reactive Protein ◽  
Significant Difference

Objectives To study the effect of angiotensin-converting enzyme (ACE) polymorphisms II, ID, and DD on erythropoietin (EPO) requirement in patients on continuous ambulatory peritoneal dialysis (CAPD) therapy. Design Retrospective observational study. Setting CAPD Unit, Royal London/St. Bartholomews Hospital, London, UK. Patients 46 patients on the transplant waiting list (age 20 – 70 years), on CAPD therapy for an average of 28 months, seen consecutively over a period of 3 months in the outpatients department. Main Outcome Measures Primary end point: EPO dose requirement in different ACE genotypes. Secondary end points: C-reactive protein, ferritin, parathyroid hormone, Kt/V, duration of dialysis, folate, cause of renal failure, and whether or not patients were on ACE inhibitor therapy. Results There was a statistically significant difference ( p < 0.05) in EPO requirement in the II/ID group compared to the DD group. The mean ± standard error of EPO for the II/ID group was 144 ± 15 U/kg/week, and for the DD group, 87 ± 9 U/kg/ week. The difference in EPO requirement could not be explained by age, C-reactive protein, ferritin, parathyroid hormone, Kt/V, duration of dialysis, folate, cause of renal failure, or whether or not patients were on ACE inhibitor therapy. Conclusion In CAPD patients, ACE genotype has predictive value when determining the EPO dosage, as the II/ID genotype may be associated with a suboptimal response.

Sign in / Sign up

Export Citation Format

Share Document